Implication of the toll‐like receptor 4 pathway in the response to interferon‐β in multiple sclerosis
- 7 June 2011
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 70 (4) , 634-645
Abstract
Objective: Interferon‐beta (IFNβ) has demonstrated beneficial effects reducing disease activity in multiple sclerosis (MS) patients, but a relatively large proportion of patients do not respond to treatment. Here we aimed to investigate the roles of the Toll‐like receptor 4 (TLR4) and the type I IFN pathways in the response to IFNβ in MS patients.Methods: The expression levels of several components of the TLR4 and the type I IFN pathways were determined by flow cytometry and real‐time polymerase chain reaction (PCR) in peripheral blood mononuclear cells (PBMCs) from a cohort of 85 MS patients treated for at least 2 years with IFNβ and classified into responders, intermediate responders, and nonresponders based on their clinical response to treatment. Thirty‐two healthy controls were also included in the study for comparison purposes.Results: Compared to responders and controls, PBMCs from nonresponders and intermediate responders were characterized by increased baseline expression levels of endogenous IFNβ and elevated IFN receptor 1 (IFNAR1) expression in monocytes. Furthermore, the capacity of IFNβ to induce its own expression was deficient in cells from nonresponders compared with responders. Baseline expression of the interleukin‐1 receptor‐associated kinase 3 (IRAK3), a negative regulator of TLR4 signaling primarily expressed in monocytes, was found to be significantly decreased in IFNβ responders compared with nonresponders.Interpretation: These findings provide evidence of the involvement of the TLR4 and type I IFN signaling pathways in the response to IFNβ. ANN NEUROL 2011;70:634–645Keywords
This publication has 20 references indexed in Scilit:
- Demonstration of increased toll-like receptor 2 and toll-like receptor 4 expression in monocytes of type 1 diabetes mellitus patients with microvascular complicationsMetabolism, 2011
- T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitisNature Medicine, 2010
- A type I interferon signature in monocytes is associated with poor response to interferon-β in multiple sclerosisBrain, 2009
- 'Fine tuning' TLR signalingNature Immunology, 2008
- Phosphatase SHP-1 promotes TLR- and RIG-I-activated production of type I interferon by inhibiting the kinase IRAK1Nature Immunology, 2008
- TAM Receptors Are Pleiotropic Inhibitors of the Innate Immune ResponseCell, 2007
- Toll-like receptors and innate immunityJournal of Molecular Medicine, 2006
- Defining the response to interferon‐β in relapsing‐remitting multiple sclerosis patientsAnnals of Neurology, 2006
- Assessment of different treatment failure criteria in a cohort of relapsing–remitting multiple sclerosis patients treated with interferon β: Implications for clinical trialsAnnals of Neurology, 2002
- IRAK-M Is a Negative Regulator of Toll-like Receptor SignalingCell, 2002